Aug 18, 2017, 01:02 AM




Leave a comment



A portfolio of highly differentiated products, all of which demonstrate strong, sustainable growth.

Uni-Bio Science develops and commercialises innovative biopharmaceuticals. Since 2001, we have been bringing high quality science and treatments to patients in China. Our highly differentiated products are focused on the treatment of chronic diseases in endocrinology such as diabetes, ophthalmology and dermatology. In their respective classes, our products consistently demonstrate clear clinical advantages over treatments that are currently on the market. 

Uni-Bio Science has a strong and diverse sales and marketing footprint in the key cities of China, and is actively broadening its reach through the continuation and development of our long-term sales forces expansion initiatives.

The Group's commercial team leverages decades of sales and marketing management experience from international pharmaceutical companies, as well as excellent local market knowledge in driving revenue growth. 

Besides its growing internal capabilities, the Group recently began to reap the benefits of  its earlier partnering strategies as Mitiglinide, an oral anti-diabetic drug acquired from Jiangsu Hansoh Pharmaceutical Co. Ltd, was launched to the market in April 2017, starting to generate revenue for the Group.